Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic s… Read more
Steminent Biotherapeutics Inc. (7729) - Total Assets
Latest total assets as of June 2025: NT$377.35 Million TWD
Based on the latest financial reports, Steminent Biotherapeutics Inc. (7729) holds total assets worth NT$377.35 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Steminent Biotherapeutics Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Steminent Biotherapeutics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Steminent Biotherapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Steminent Biotherapeutics Inc.'s total assets of NT$377.35 Million consist of 54.0% current assets and 46.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 47.0% |
| Accounts Receivable | NT$266.00K | 0.1% |
| Inventory | NT$12.00 Million | 2.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$2.39 Million | 0.6% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Steminent Biotherapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Steminent Biotherapeutics Inc.'s current assets represent 54.0% of total assets in 2024, an increase from 53.6% in 2020.
- Cash Position: Cash and equivalents constituted 47.0% of total assets in 2024, up from 40.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 2.8% of total assets.
Steminent Biotherapeutics Inc. Competitors by Total Assets
Key competitors of Steminent Biotherapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Steminent Biotherapeutics Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Steminent Biotherapeutics Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Steminent Biotherapeutics Inc. is currently not profitable relative to its asset base.
Steminent Biotherapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.33 | 12.57 | 6.68 |
| Quick Ratio | 5.98 | 12.07 | 6.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$156.48 Million | NT$ 311.27 Million | NT$ 137.03 Million |
Steminent Biotherapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Steminent Biotherapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -26.5% |
| Total Assets | NT$436.66 Million |
| Market Capitalization | $24.45K USD |
Valuation Analysis
Below Book Valuation: The market values Steminent Biotherapeutics Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Steminent Biotherapeutics Inc.'s assets decreased by 26.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Steminent Biotherapeutics Inc. (2020–2024)
The table below shows the annual total assets of Steminent Biotherapeutics Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$436.66 Million | -26.47% |
| 2023-12-31 | NT$593.88 Million | +152.02% |
| 2022-12-31 | NT$235.65 Million | -15.69% |
| 2021-12-31 | NT$279.50 Million | +178.99% |
| 2020-12-31 | NT$100.18 Million | -- |